Inclusion of biomarkers: tumor grade, hormone receptors, and HER2 (in countries where these are widely available). Inclusion of multi-gene panels. The clinical prognostic stage is assigned regardless of the type of therapy received. Pathologic prognostic stage will be assigned to patients who underwent surgery as initial treatment (excludes patients who received neoadjuvant therapy). This evidence concerns the gene ERBB2 and neoplasm.